AnaptysBio (NASDAQ:ANAB) Trading Up 3.6%

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price traded up 3.6% during mid-day trading on Tuesday . The stock traded as high as $22.04 and last traded at $22.03. 27,661 shares traded hands during trading, a decline of 91% from the average session volume of 309,706 shares. The stock had previously closed at $21.27.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Stifel Nicolaus assumed coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price target for the company. Piper Sandler assumed coverage on AnaptysBio in a report on Friday, February 16th. They set an “overweight” rating and a $80.00 price target for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a report on Tuesday. Wells Fargo & Company assumed coverage on AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Stock Up 0.6 %

The company has a market cap of $574.54 million, a price-to-earnings ratio of -3.53 and a beta of -0.30. The stock has a fifty day moving average price of $23.38 and a two-hundred day moving average price of $20.55.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The company had revenue of $9.01 million for the quarter, compared to analysts’ expectations of $3.28 million. Analysts predict that AnaptysBio, Inc. will post -6.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total value of $72,425.95. Following the transaction, the chief financial officer now owns 964 shares in the company, valued at $22,779.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total value of $72,425.95. Following the transaction, the chief financial officer now owns 964 shares in the company, valued at $22,779.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Daniel Faga sold 3,000 shares of AnaptysBio stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 157,005 shares of company stock worth $3,586,199. Company insiders own 35.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in AnaptysBio in the second quarter valued at about $34,000. Tower Research Capital LLC TRC grew its position in AnaptysBio by 248.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 2,565 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 2,390 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 2,142 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in AnaptysBio by 134.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after acquiring an additional 3,381 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.